Pacira Biosciences Inc Stock Price, News & Analysis

Pacira BioSciences (Nasdaq: PCRX) reported preliminary net product sales of $54.9 million for October 2022, driven by continued growth in EXPAREL, ZILRETTA, and iovera° sales. EXPAREL net sales reached $45.0 million, up from $42.5 million in October 2021, with average daily sales increasing by 106%. Despite recent challenges from COVID-19 affecting elective surgeries, the company maintains confidence for double-digit growth and plans for new market expansions. No 2022 revenue guidance was provided due to ongoing uncertainties.

Pacira BioSciences, Inc. (NASDAQ: PCRX) announced participation in upcoming healthcare conferences. The company will engage in an analyst-led fireside chat at the Jefferies London Healthcare Conference on November 15 at 8:00 AM GMT and the 34th Annual Piper Sandler Healthcare Conference on November 29 at 2:30 PM ET. Live audio can be accessed on their website, with replays available for two weeks post-event. Pacira is dedicated to offering non-opioid pain management options and has three commercial products for pain relief.

Pacira BioSciences reported a 31% increase in revenue to $167.5 million for Q3 2022, with net product sales of $132.6 million for EXPAREL. The company experienced a net loss of $0.7 million or $(0.02) per share, contrasting with a profit in Q3 2021. Adjusted EBITDA rose to $55.2 million, up from $48.1 million a year prior. Notably, the company received a new patent for EXPAREL, extending exclusivity until 2041, and reported positive results from Phase 3 studies, enhancing its product portfolio and potential revenue streams.

Pacira BioSciences, Inc. (NASDAQ:PCRX) will release its third quarter financial results on November 3, 2022, before U.S. markets open. A live conference call will follow at 8:30 a.m. ET, allowing participants to engage in a Q&A session. Pre-registration for telephone participation is required. The company, known for its non-opioid pain management solutions, aims to redefine opioid use and has three commercial-stage products: EXPAREL, ZILRETTA, and iovera. A webcast of the call will be available for those unable to attend live.

Pacira BioSciences (PCRX) reported preliminary revenues of $167.5 million for Q3 2022, a significant increase from $127.7 million in Q3 2021. EXPAREL sales reached $132.6 million for Q3 2022, showing a 109% increase year-over-year. In September, daily sales rose 113% compared to the previous year. The company remains optimistic about revenue growth despite ongoing challenges from COVID-19 and the elective surgery market. No guidance for 2022 revenue or gross margin is provided due to ongoing uncertainties.

Pacira BioSciences (Nasdaq: PCRX) has partnered with Sevāredent Sourcing Solutions to enhance access to EXPAREL (bupivacaine liposome injectable suspension) for pain management in oral and maxillofacial surgeries. This initiative will benefit over 1,800 dental offices across the U.S. by providing comprehensive training and support to reduce opioid exposure. The collaboration aims to improve patient outcomes and align with the growing demand for non-opioid alternatives amid the opioid crisis.

Pacira BioSciences (PCRX) announced positive topline results from its Phase 3 study of EXPAREL for postsurgical pain management in bunionectomy patients. The study demonstrated a statistically significant reduction in pain scores and opioid consumption compared to bupivacaine HCl, meeting both primary and secondary endpoints (p<0.00001). The company plans to submit a supplemental New Drug Application early in 2023 to expand EXPAREL's label for new indications. The results position EXPAREL as a groundbreaking option for regional analgesia, aiming to enhance patient outcomes while minimizing opioid use.

Pacira BioSciences announced a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorization for an expanded indication of EXPAREL in children aged 6 years and older. This allows for its use as a field block for somatic post-operative pain management from small- to medium-sized surgical wounds. The approval is based on the Phase 3 PLAY study, involving 98 pediatric patients, which showed safety and pharmacokinetic profiles similar to those in adults. A European Commission decision is expected by November 2022.

Pacira BioSciences, Inc. (Nasdaq: PCRX) reported preliminary unaudited net product sales of $59.1 million for August 2022, driven by EXPAREL sales totaling $46.7 million, up from $41.4 million in August 2021. The average daily sales for EXPAREL reached 108% of the previous year. The company has also surpassed 11 million patients treated with EXPAREL. Despite positive sales trends, Pacira refrained from providing 2022 revenue guidance due to lingering uncertainties from COVID-19 and its impact on elective surgeries.